This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
CCXI Panoramica delle azioni
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
Punteggio fiocco di neve | |
---|---|
Valutazione | 2/6 |
Crescita futura | 5/6 |
Prestazioni passate | 0/6 |
Salute finanziaria | 4/6 |
Dividendi | 0/6 |
ChemoCentryx, Inc. Concorrenti
Storia dei prezzi e prestazioni
Prezzi storici delle azioni | |
---|---|
Prezzo attuale dell'azione | US$51.99 |
Massimo di 52 settimane | US$52.00 |
Minimo di 52 settimane | US$14.95 |
Beta | 1.23 |
1Variazione di 1 mese | 0.41% |
Variazione a 3 mesi | 134.51% |
Variazione di 1 anno | 50.39% |
3Variazione a 3 anni | 558.10% |
Variazione a 5 anni | 642.71% |
Variazione dall'IPO | 372.64% |
Notizie e aggiornamenti recenti
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Rendimenti per gli azionisti
CCXI | US Biotechs | US Mercato | |
---|---|---|---|
7D | 0.1% | -0.5% | 0.4% |
1Y | 50.4% | 18.3% | 32.6% |
Ritorno vs Industria: CCXI exceeded the US Biotechs industry which returned -1.9% over the past year.
Rendimento vs Mercato: CCXI exceeded the US Market which returned -19.8% over the past year.
Volatilità dei prezzi
CCXI volatility | |
---|---|
CCXI Average Weekly Movement | 31.3% |
Biotechs Industry Average Movement | 9.9% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: CCXI's share price has been volatile over the past 3 months.
Volatilità nel tempo: CCXI's weekly volatility has increased from 18% to 31% over the past year.
Informazioni sull'azienda
Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
---|---|---|---|
1996 | 178 | n/a | www.chemocentryx.com |
ChemoCentryx, Inc. Riepilogo dei fondamenti
CCXI statistiche fondamentali | |
---|---|
Capitalizzazione di mercato | US$3.74b |
Guadagni(TTM) | -US$133.09m |
Ricavi(TTM) | US$37.28m |
100.3x
Rapporto P/S-28.1x
Rapporto P/ECCXI è sopravvalutato?
Vedi Fair Value e analisi di valutazioneGuadagni e ricavi
CCXI Conto economico (TTM) | |
---|---|
Ricavi | US$37.28m |
Costo del fatturato | US$71.86m |
Profitto lordo | -US$34.58m |
Altre spese | US$98.51m |
Guadagni | -US$133.09m |
Ultimi guadagni dichiarati
Jun 30, 2022
Prossima data di guadagno
n/a
Utile per azione (EPS) | -1.85 |
Margine lordo | -92.76% |
Margine di profitto netto | -357.01% |
Rapporto debito/patrimonio netto | 10.5% |
Come si è comportato CCXI nel lungo periodo?
Vedi performance storica e confronto